Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a higher aspirin dose shield High-Risk pregnancies from preeclampsia?

NCT ID NCT07779057

Prevention Sponsor: Medicare Hospital (Pvt) Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether a higher dose of aspirin (150 mg) prevents preeclampsia better than the standard low dose (75 mg) in pregnant women at high risk. Participants take their assigned dose nightly from early pregnancy until 36 weeks, and researchers track who develops preeclampsia, stillbirth rates, and newborn birth weight. The goal is to find the most effective aspirin dose to protect both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin (acetylsalicylic acid) taken orally once daily at bedtime from 11-14 weeks of pregnancy until 36 weeks
What this could lead to
If a higher dose works better, it could offer a simple, low-cost way to reduce preeclampsia risk in high-risk pregnancies, potentially improving outcomes for mothers and babies.
What could go wrong
This is a small, early-phase trial, so results may not be conclusive. Higher-dose aspirin may increase bleeding risk, and the benefit over the standard dose is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gestational age 11-14 weeks * High risk of preeclampsia Exclusion Criteria: * Active gastritis * Abnormal coagulation profile (INR \> 1.5) * Renal disease * Platelet count \< 150,000/mm\^3 * Fetal malformations * Vaginal bleeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Birth Weight Stillbirth preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medicare Hospital (Pvt) Ltd.

    RECRUITING

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.